ReviewCurrent atherosclerosis reports2005
Pleiotropic effects of statins: moving beyond cholesterol control.
Review in Current atherosclerosis reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00721305 (Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)
Who cites it
5 citing papers in PubMed, 21 citations in OpenAlex.
- Trial
- Anti-inflammatory and chondroprotective effects of atorvastatin in a cartilage explant model of osteoarthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Article
- Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.Discovery medicine · 2013Review
- Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy.Clinical cardiology · 2005Review
- Clinical implications of pharmacogenomics of statin treatment.The pharmacogenomics journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or "statin" medications are the most commonly prescribed therapy for lowering cholesterol. In use for over a decade, they have demonstrated both safety and tolerability across a broad range of patients. The ability to inhibit the biosynthesis of cholesterol and reduce low-density lipoprotein cholesterol levels is known to play a major part in reducing cardiovascular risk. Multiple clinical trials have cemented their role in both primary and secondary prevention of atherosclerotic disease. Clinical evidence also supports the principle that reductions in cardiovascular risk are interdependent on mechanisms beyond cholesterol reduction alone. These pleiotropic effects of statins have underscored a widening focus and understanding into the mechanisms of vascular dysfunction, inflammation, and injury. They have also brought a new perspective to a broad spectrum of clinical uses that has implications for specialties as varied as infectious disease, rheumatology, and oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.